22% Organic Growth for Q3/202328% Organic Growth for the Frist 9 Months of 202322% Higher Revenue Over Q3/202233% Higher Revenue Over First 9 Months of.
Financial results represent clinical trials progress with recruitment at a pace faster than expected in CM24 Phase 2 studyClinical data from both studies.